A
Archana Narasanna
Researcher at Vanderbilt University
Publications - 12
Citations - 1355
Archana Narasanna is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Lapatinib & Receptor tyrosine kinase. The author has an hindex of 8, co-authored 12 publications receiving 1260 citations. Previous affiliations of Archana Narasanna include University of Texas Southwestern Medical Center & Harvard University.
Papers
More filters
Journal ArticleDOI
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Shizhen Emily Wang,Archana Narasanna,Marianela Perez-Torres,Bin Xiang,Frederick Y. Wu,Seungchan Yang,Graham Carpenter,Adi F. Gazdar,Senthil K. Muthuswamy,Carlos L. Arteaga +9 more
TL;DR: It is suggested that Her2(YVMA) activates cellular substrates more potently than HER2(WT); and cancer cells expressing this mutation remain sensitive to HER2-targeted therapies but insensitive to EGFR TKIs.
Journal ArticleDOI
Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers
Bhuvanesh Dave,Ilenia Migliaccio,M. Carolina Gutierrez,Meng Fen Wu,Gary C. Chamness,Helen Wong,Archana Narasanna,Anindita Chakrabarty,Susan G. Hilsenbeck,Jian Huang,Mothaffar F. Rimawi,Rachel Schiff,Carlos L. Arteaga,C. Kent Osborne,Jenny C. Chang +14 more
TL;DR: Activation of PI3 kinase pathway is associated with trastuzumab resistance, whereas low PTEN predicted for response to lapatinib, and these observations support clinical trials with the combination of both agents.
Journal ArticleDOI
Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Ritwik Ghosh,Archana Narasanna,Shizhen Emily Wang,Shuying Liu,Anindita Chakrabarty,Justin M. Balko,Ana M. Gonzalez-Angulo,Gordon B. Mills,Elicia Penuel,John Winslow,Jeff Sperinde,Rajiv Dua,Sailaja Pidaparthi,Ali Mukherjee,Kim Leitzel,Wolfgang J. Köstler,Allan Lipton,Michael Bates,Carlos L. Arteaga +18 more
TL;DR: The notion that HER2 oligomeric states regulate HER2 signaling is confirmed, also arguing that trastuzumab sensitivity of homodimers may reflect their inability to activate the PI3K (phosphoinositide 3-kinase)/AKT pathway.
Journal ArticleDOI
Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer
Todd W. Miller,Marianela Perez-Torres,Archana Narasanna,Marta Guix,Olle Stål,Gizeh Pérez-Tenorio,Ana M. Gonzalez-Angulo,Bryan T. Hennessy,Gordon B. Mills,J. Phillip Kennedy,Craig W. Lindsley,Carlos L. Arteaga +11 more
TL;DR: PTEN levels inversely correlated with levels of tyrosine-phosphorylated IGF-IR in tissue lysate arrays of primary breast cancers, suggesting that cotargeting both ER and receptor tyrosinesine kinase pathways holds promise for the treatment of patients with ER+, PTEN-deficient breast cancers.
Journal ArticleDOI
Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells
Todd W. Miller,James T. Forbes,Chirayu Shah,Shelby K. Wyatt,H. Charles Manning,Maria Graciela Olivares,Violeta Sanchez,Teresa C. Dugger,Nara de Matos Granja,Archana Narasanna,Rebecca S. Cook,J. Phillip Kennedy,Craig W. Lindsley,Carlos L. Arteaga +13 more
TL;DR: The combined use of trastuzumab and mTOR inhibitors for the treatment of HER2+ breast cancer and the signaling and growth effects of the mTOR inhibitor RAD001 on HER2-overexpressing breast cancers were evaluated.